Small-Scale Bioreactors Market Set To Touch $5.32 billion By 2032: Players Thermo Fisher Scientific Inc., Sartorius AG

As per the report published by The Brainy Insights, the global small-scale bioreactors market is expected to grow from USD 1.56 billion in 2022 to USD 5.32 billion by 2032, at a CAGR of 13.05% during the forecast period 2023-2032. North America region emerged as the largest global small-scale bioreactors market, with a 48.22% market revenue share in 2022. The increase in the number of personalized medicines and the local presence of several service providers are propelling the market's growth in this region. Furthermore, the rising prevalence of chronic diseases and the increasing demand for monoclonal antibodies and biosimilars are anticipated to drive market growth in this region. In addition, the Asia Pacific region is expected to show the fastest CAGR growth over the projection period due to the high volume of large molecule production.

Download Exclusive Sample of this Premium Report @ https://www.thebrainyinsights.com/enquiry/sample-request/13395

Leading companies in the industry include Thermo Fisher Scientific Inc., Sartorius AG, Eppendorf AG, Lonza Group, Merck KGaA, Eppendorf AG, Danaher Corp, Solaris Biotechnology Srl, Getinge AB, Miltenyi Biotec, Infors AG, and among others which are offering greater opportunities and are continuously focused on new product developments and venture capital investments to obtain market share.

The capacity segment is divided into 5 ML -100 ML, 100 ML-250 ML, 250 ML -500 ML, 500 ML-1 L, 1L-3L, and 3L-5L. The 1L-3L segment led the market with a market share of 23.18% in 2022. This growth is attributed to the technological advancements in single-use bioreactors. The product segment is divided into single-use bioreactors and reusable bioreactors. The reusable bioreactors sub-segment is divided into glass bioreactors and stainless-steel bioreactors. The single-use bioreactors segment led the market with a market share of 56.21% in 2022. This growth is attributed to the rising number of R&D activities in the biopharmaceutical field. The end-user segment is divided into CROs & CMOs, pharmaceutical & biopharmaceutical companies, and academic & research institutes. The CROs & CMOs segment led the market with a market share of 45.13% in 2022. This growth is attributed to the growing interest of conventional drug developers in biological therapeutics.

The technological advances in bioreactors, significant R&D investments, coupled with the ease in the cultivation of marine organisms are helping to drive the growth of the small-scale bioreactors market. Further, increased demand for novel biologic drugs, the rise in demand for monoclonal antibiotics, coupled with the increase in funding from private & public organizations for vaccine development, and the surge in demand for single-use bioreactors are helping to stimulate the small-scale bioreactors market growth during the forecast period. Additionally, the rapid adoption of disposable technology in the biotechnology and pharmaceutical industry is also helping to boost market growth over the forecast period.

Data-licious Deals Await! Inquire Now for Purchase @ https://www.thebrainyinsights.com/report/small-scale-bioreactors-market-13395

About The Brainy Insights:
The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients' objectives of high-quality output within a short span of time. We provide both customized (clients' specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients' requirement whether they are looking to expand or planning to launch a new product in the global market.

Media Contact
Avinash D
Organization: The Brainy Insights
Phone: +1-315-215-1633
Email: sales@thebrainyinsights.com
Web: www.thebrainyinsights.com

This release was published on openPR.